A Comparison of Osseous and Extraosseous Ewing Sarcoma | [Journal of College of Physicians and Surgeons--Pakistan : JCPSP • 2021]

Author(s):

1. Selin Akturk Esen: Department of Medical Oncology, Health Sciences University, Ankara City Hospital, Ankara, Turkey

2. Yusuf Acikgoz: Department of Medical Oncology, Health Sciences University, Ankara City Hospital, Ankara, Turkey

3. Oznur Bal: Department of Medical Oncology, Health Sciences University, Ankara City Hospital, Ankara, Turkey

4. Birol Yildiz: Department of Medical Oncology, Elazığ Fethi Sekin City Hospital, Turkey

5. Gokhan Ucar: Department of Medical Oncology, Health Sciences University, Ankara City Hospital, Ankara, Turkey

6. Merve Dirikoc: Department of Medical Oncology, Health Sciences University, Ankara City Hospital, Ankara, Turkey

7. Yakup Ergun: Department of Medical Oncology, Health Sciences University, Ankara City Hospital, Ankara, Turkey

8. Efnan Algin: Department of Medical Oncology, Health Sciences University, Ankara City Hospital, Ankara, Turkey

9. Dogan Uncu: Department of Medical Oncology, Health Sciences University, Ankara City Hospital, Ankara, Turkey

Abstract:

Objective: To compare the clinicopathological characteristics, treatment responses, survival analysis of osseous Ewing sarcoma (OES) and extraosseous ES (EES). Study Design: Observational study. Place and Duration of Study: Ankara City Hospital and Ankara Numune Training Research Hospital Medical Oncology Clinics from January 2005 to February 2020. Methodology: Clinicopathological characteristics of histologically con rmed ES/PNET and followed up, and treatment modalities were recorded from patients registration data-base of the hospital. Lactate dehydrogenase (LDH)a,lkaline phosphatase (ALP), hemoglobin were measured before chemotherapy or surgery. The patients with a second cancer, gall bladder/biliary tract diseases, viral hepatitis and other bone diseases were excluded. Results: Sixty seven patients evaluated retrospectively. Out of the total patients, 56.7% consisted of OES, and 43.3% consisted of EES. The median age of the EES group (26 years) was signi cantly higher than that of the OES group (22 years, p = 0.008). The most common metastasis region was lung in both the groups. Age, LDH levels and stage of the disease were found to be statistically signi cant prognostic factors in univariate and multivariate analysis. The median OS of patients who started with local treatment (surgical, surgical ± radiotherapy) and followed up with chemotherapy was82.6 months (95% CI, 55.2-110.1), while the median OS of patients who received local treatment between or after chemotherapy was 43.4 months (95% CI, 13.2-73.6, p = 0.042). Conclusion: Patients with extrosseus ES were signi cantly older. Age, LDH levels, stage of disease, local treatment followed by systemic therapy are important associated factors.

Page(s): 27-33

DOI: DOI not available

Published: Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 31, Issue: 1, Year: 2021

Keywords:

chemotherapy , Extraosseous ewing sarcoma , Local treatment , Osseous ewing sarcoma

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views